Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Key Material For Diagnostic Agent Temporarily Stops Exporting To Japan          

This article was originally published in PharmAsia News

Executive Summary

Due to a production halt caused by reactor trouble at Atomic Energy of Canada Ltd, molybdenum 99, a key material for cancer and vascular diagnostic agents, will not be exported to Japan temporarily. Japan Radioisotope Association May 26 notified medical facilities nationwide. The production halt is expected to last for more than one month. AECL accounts for over half of worldwide molybdenum 99 production. (Click here for more - Japanese language

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071852

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel